
    
      The RSV PED-002 study, designed to evaluate the safety, reactogenicity and immunogenicity of
      the RSV candidate vaccine when administered in 3 sequential doses to seropositive infants
      aged 12 to 23 months, will be conducted in an observer-blind manner in Epoch 1 and
      single-blinded in Epoch 2.
    
  